SCHEMBL5525919

SCHEMBL5525919

Cc1ccc2c(c1)c(=O)oc(=O)n2C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
ELANE P08246 3/20 0.45
MAPT P10636 3/20 0.43
PKM P14618 2/20 0.43
HTT P42858 2/20 0.43
APAF1 O14727 1/20 0.43
IDO1 P14902 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
MCL1 Q07820 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.41
NR1I2 O75469 1/20 0.41
AHR P35869 1/20 0.41
USP2 O75604 1/20 0.39
TSHR P16473 1/20 0.39
ALDH1A1 P00352 1/20 0.38
MIF P14174 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29811263 1.00 KDM4E (0.45) KDM4EELANEMAPTPKMHTT
SCHEMBL29891982 0.86 ELANE (0.41) KDM4EELANEMAPTPKMHTT
SCHEMBL22915141 0.86 ELANE (0.41) KDM4EELANEMAPTPKMHTT
SCHEMBL29811258 0.81 PKM (0.44) KDM4EMAPTPKMHTTMAPK1
SCHEMBL22239410 0.81 PDE2A (0.46) PKMNPSR1ALDH1A1BCHEACHE
SCHEMBL4822294 0.81 ATM (0.45) KDM4EPKMKMT2AMEN1ALDH1A1
SCHEMBL607256 0.81 PKM (0.44) KDM4EMAPTPKMHTTMAPK1
SCHEMBL29811309 0.81 ESR2 (0.41) MAPTHTTMAPK1RAB9AMCL1
SCHEMBL2384145 0.81 ESR2 (0.41) MAPTHTTMAPK1RAB9AMCL1
SCHEMBL29811388 0.81 ATM (0.45) KDM4EPKMKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110511188-B Preparation method of 2-imino dihydro quinazolinone compound 烟台大学 2022-09-20 CN claimed
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2025-11-25 US disclosed
CN-119564686-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-03-07 CN disclosed
CN-119523983-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-28 CN disclosed
CN-119424429-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-14 CN disclosed
CN-115003665-B DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2024-11-08 CN disclosed
US-11998539-B2 Substituted aminoquinolones as DGKalpha inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-06-04 US disclosed
US-20240140949-A1 ANTI-CANCER PHARMACEUTICAL COMPOSITION FOR TARGETING HEAT SHOCK PROTEIN 70, CONTAINING INDOLOQUINAZOLIDINE ALKALOID SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) 2024-05-02 US disclosed
US-20230201186-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-29 US disclosed
US-20230201186-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-29 US disclosed
US-7173036-B2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same AVANIR PHARMACEUTICALS (US) 2007-02-06 US disclosed
US-20040204586-A1 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same AVANIR PHARMACEUTICALS, INC. 2004-10-14 US disclosed
EP-0135367-B1 THERAPEUTIC AGENTS The Boots Company PLC (GB) 1988-03-16 EP disclosed
US-4659718-A VASODILATION THE BOOTS COMPANY PLC (GB) 1987-04-21 US disclosed
US-4537966-A 1-(Aminobenzoyl)-1H-indazol-3-ols PENNWALT CORPORATION (US) 1985-08-27 US disclosed
EP-0135367-A1 Therapeutic agents The Boots Company PLC (GB) 1985-03-27 EP disclosed
EP-0015065-B1 PYRAZOLO (5,1-B) QUINAZOLIN-9(4H)-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM WARNER-LAMBERT COMPANY (US) 1983-12-28 EP disclosed
US-4261997-A 4-Alkyl-pyrazolo[5,1-b]-quinazolin-9(4H)-ones and anti-allergic compositions containing them WARNER-LAMBERT COMPANY (US) 1981-04-14 US disclosed
EP-0015065-A1 Pyrazolo (5,1-b) quinazolin-9(4H)-one derivatives, process for their preparation and pharmaceutical compositions containing them WARNER-LAMBERT COMPANY (US) 1980-09-03 EP disclosed
US-3947408-A ANTIANXIETY AGENTS AMERICAN CYANAMID COMPANY (US) 1976-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DGKK, DGKG, DGKA KDM4E 1315/4885ELANE 3411/4885MAPT 4812/4885
US-11998539-B2 Substituted aminoquinolones as DGKalpha inhibitors for immune activation DGKK, DGKG, DGKA KDM4E 1315/4885ELANE 3411/4885MAPT 4812/4885
US-20040204586-A1 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same MIF, MSR1, MMP12 KDM4E 3206/4885ELANE 35/4885MAPT 4793/4885
US-20230201186-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION DGKK, DGKG, DGKA KDM4E 1315/4885ELANE 3411/4885MAPT 4812/4885
US-20240140949-A1 ANTI-CANCER PHARMACEUTICAL COMPOSITION FOR TARGETING HEAT SHOCK PROTEIN 70, CONTAINING INDOLOQUINAZOLIDINE ALKALOID HSPH1, HSP90AB2P, HSPBP1 KDM4E 3757/4885ELANE 4798/4885MAPT 864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.